South Africa has 57,471 active cases of Covid-19.



South Africa has 57,471 active Covid-19 cases out of 3,931,534 confirmed cases and 3,773,111 recoveries.

Over the past day, 1,662 new cases of Covid-19 infection have been detected in the country. This increase represents a 13.7% positive rate, according to the National Institute of Infectious Diseases (NICD), a division of the National Health Laboratory Service, announced.

25,081,137 tests were carried out in both the public and private sectors. Today, the majority of new cases are in Gauteng (39%), followed by the Western Cape (22%). KwaZulu-Natal accounted for 13%; The Free State accounted for 6%; Mpumalanga and North West accounted for 5% each, respectively; The Eastern Cape and Northern Cape were 4% each, respectively; and Limpopo accounts for 1% of today’s cases.

The NICD reported 19 deaths, of which 8 occurred in the last 24–48 hours. This brings the total death toll to date to 100,952.

“Due to ongoing audits by the National Department of Health (NDoH), there may be a buildup of reports of Covid-19 deaths.”

Over the past 24 hours, the number of hospitalizations has increased by 83.

Pfizer Covid-19 vaccine for children under five is effective at three doses

The Pfizer-BioNTech Covid vaccine is safe and effective when given three times to children under the age of five, the companies said on Monday.

The announcement comes after the U.S. Food and Drug Administration (FDA) plans to hold highly anticipated meetings in the coming weeks to weigh in on approval.

In a clinical trial, Pfizer-BioNTech evaluated three doses of three micrograms and found that the vaccine elicited a strong immune response in children aged six months to four years.

Side effects were similar in the vaccine and placebo groups.

The preliminary estimate was that the vaccine was 80.3 percent effective, although this was based on very low numbers and could change significantly by the time of the final assessment.

“We are delighted that our formulation for youngest children, which we carefully selected to be one-tenth the adult dose, was well tolerated and elicited a strong immune response,” Pfizer CEO Albert Burla said in a statement.

“We look forward to completing our global regulatory submissions soon, with the hope of making this vaccine available to young children as quickly as possible, subject to regulatory approval,” he added.

Additional AFP reporting